›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:AVENIO Tumor Tissue Targeted Kit
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
RocheType:
Laboratory Developed Test
Related tests:
The AVENIO Tumor Tissue Targeted Kit is a next-generation sequencing (NGS) assay for comprehensive genomic profiling of solid tumors from formalin-fixed paraffin-embedded (FFPE) tissue samples. It features all four mutation classes (SNVs, indels, fusions and CNVs) in a single DNA workflow with exceptional sensitivity and specificity. It has 99% success rate for FFPE tissue samples that pass input QC testing using the AVENIO QC kit included with the assay.
Cancer:
Solid Tumor
Gene:
ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), DPYD (Dihydropyrimidine Dehydrogenase)
See More ...
ALK (Anaplastic lymphoma kinase), APC (APC Regulator Of WNT Signaling Pathway), BRAF (B-raf proto-oncogene), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), DPYD (Dihydropyrimidine Dehydrogenase), EGFR (Epidermal growth factor receptor), HER-2 (Human epidermal growth factor receptor 2), KIT (KIT proto-oncogene, receptor tyrosine kinase), KRAS (KRAS proto-oncogene GTPase), MET (MET proto-oncogene, receptor tyrosine kinase), NRAS (Neuroblastoma RAS viral oncogene homolog), PDGFRA (Platelet Derived Growth Factor Receptor Alpha), RET (Ret Proto-Oncogene), ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS), TP53 (Tumor protein P53), UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
Method:
Next-Generation Sequencing (NGS)
